Literature DB >> 22408277

Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown.

Ying Yuan1, Peter F Thall, Johannes E Wolff.   

Abstract

In oncology, progression-free survival time, which is defined as the minimum of the times to disease progression or death, often is used to characterize treatment and covariate effects. We are motivated by the desire to estimate the progression time distribution on the basis of data from 780 paediatric patients with choroid plexus tumours, which are a rare brain cancer where disease progression always precedes death. In retrospective data on 674 patients, the times to death or censoring were recorded but progression times were missing. In a prospective study of 106 patients, both times were recorded but there were only 20 non-censored progression times and 10 non-censored survival times. Consequently, estimating the progression time distribution is complicated by the problems that, for most of the patients, either the survival time is known but the progression time is not known, or the survival time is right censored and it is not known whether the patient's disease progressed before censoring. For data with these missingness structures, we formulate a family of Bayesian parametric likelihoods and present methods for estimating the progression time distribution. The underlying idea is that estimating the association between the time to progression and subsequent survival time from patients having complete data provides a basis for utilizing covariates and partial event time data of other patients to infer their missing progression times. We illustrate the methodology by analysing the brain tumour data, and we also present a simulation study.

Entities:  

Year:  2012        PMID: 22408277      PMCID: PMC3298417          DOI: 10.1111/j.1467-9876.2011.01002.x

Source DB:  PubMed          Journal:  J R Stat Soc Ser C Appl Stat        ISSN: 0035-9254            Impact factor:   1.864


  8 in total

1.  Radiation therapy and survival in choroid plexus carcinoma.

Authors:  J E Wolff; M Sajedi; M J Coppes; R A Anderson; R M Egeler
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

2.  Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring.

Authors:  A Rotnitzky; D Scharfstein; T L Su; J Robins
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

3.  Multiple imputation methods for estimating regression coefficients in the competing risks model with missing cause of failure.

Authors:  K Lu; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

4.  A Bayesian chi-squared goodness-of-fit test for censored data models.

Authors:  Jing Cao; Ann Moosman; Valen E Johnson
Journal:  Biometrics       Date:  2009-07-23       Impact factor: 2.571

5.  Inferences on the association parameter in copula models for bivariate survival data.

Authors:  J H Shih; T A Louis
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

6.  Nonparametric estimation for partially-complete time and type of failure data.

Authors:  G E Dinse
Journal:  Biometrics       Date:  1982-06       Impact factor: 2.571

7.  Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.

Authors:  Brigitte Wrede; Martin Hasselblatt; Ove Peters; Peter F Thall; Tezer Kutluk; Albert Moghrabi; Anita Mahajan; Stefan Rutkowski; Blanca Diez; Xuemei Wang; Torsten Pietsch; Rolf-Dieter Kortmann; Werner Paulus; Astrid Jeibmann; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2009-06-20       Impact factor: 4.130

8.  Choroid plexus tumours.

Authors:  J E A Wolff; M Sajedi; R Brant; M J Coppes; R M Egeler
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.